2022
Clinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective
Batra RK, Mulligan DC. Clinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective. Liver Transplantation 2022, 28: 760-762. PMID: 34931433, DOI: 10.1002/lt.26395.Peer-Reviewed Original Research
2021
Developing simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy
Wilk AR, Booker SE, Stewart DE, Wiseman A, Gauntt K, Mulligan D, Formica RN. Developing simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy. American Journal Of Transplantation 2021, 21: 3593-3607. PMID: 34254434, DOI: 10.1111/ajt.16761.Peer-Reviewed Original ResearchConceptsMedical Eligibility CriteriaEligibility criteriaLiver transplantPatient/graft survivalWaitlist mortality rateDeceased donor kidneysLiver recipientsSLK candidatesSLK transplantsGraft survivalRenal impairmentPosttransplant outcomesDonor kidneysTransplant ratesTransplant volumeMortality rateTransplantKidneySignificant differencesRecipientsSubsequent increaseLiver dataCriteriaImpairmentSLK
2019
Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death
Valentino PL, Emre S, Geliang G, Li L, Deng Y, Mulligan D, Rodriguez-Davalos M. Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death. American Journal Of Transplantation 2019, 19: 3114-3123. PMID: 31152483, DOI: 10.1111/ajt.15481.Peer-Reviewed Original ResearchConceptsAdult recipientsTransplantation Network/United NetworkNumber of allograftsOrgan Sharing dataSplit-liver transplantationCareful patient selectionDeceased donor liversNumber of LTLT graftSLT recipientsUnderwent LTWLT recipientsPediatric candidatesPatient selectionDonor liversOrgan utilizationUnited NetworkOrgan shortageOrgan procurementSmall childrenRecipientsTransplantation
2016
De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemiaThe impact of broader regional sharing of livers: 2‐year results of “Share 35”
Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2‐year results of “Share 35”. Liver Transplantation 2016, 22: 399-409. PMID: 26890858, DOI: 10.1002/lt.24418.Peer-Reviewed Original ResearchConceptsWaiting list mortalityLiver transplantLiver diseaseEnd-stage liver disease candidatesEnd-stage liver diseasePosttransplant survival outcomesChronic liver diseaseCold ischemia timeShare 35 policyRegional sharingBroader regional sharingPost-policy periodPosttransplant graftUrgent groupIschemia timePatient survivalSurvival outcomesMedian MELDMortality rateSickest candidatesOrgan procurementTransplantation NetworkTransplantAge groupsUrgent patients
2010
Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Reddy K, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin. Transplantation Proceedings 2010, 42: 2006-2008. PMID: 20692393, DOI: 10.1016/j.transproceed.2010.05.090.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumCreatinineDrug Therapy, CombinationGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMycophenolic AcidPancreas TransplantationPatient SelectionRetrospective StudiesConceptsRapid steroid taperAcute rejection episodesR-ATG groupR-ATGSimultaneous kidneySteroid taperBK nephropathyRejection episodesPancreas transplantationAlemtuzumab groupClinical acute rejection episodesRabbit antithymocyte globulin inductionAntithymocyte globulin inductionR-ATG inductionMean serum creatinineHistoric control groupPostoperative day 4Alemtuzumab inductionAntithymocyte globulinGlobulin inductionMaintenance immunosuppressionTransplant characteristicsGraft survivalCMV infectionCytomegalovirus infection
2009
Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2008
Living donor liver transplantation in polycystic liver disease
Mekeel KL, Moss AA, Reddy KS, Douglas DD, Vargas HE, Carey EJ, Byrne TJ, Harrison ME, Rakela J, Mulligan DC. Living donor liver transplantation in polycystic liver disease. Liver Transplantation 2008, 14: 680-683. PMID: 18433036, DOI: 10.1002/lt.21423.Peer-Reviewed Original ResearchConceptsPolycystic liver diseaseDonor liver transplantationLiver transplantationLiver diseaseLiver functionEnd-Stage Liver Disease (MELD) systemDeceased donor liver transplantDonor liver transplantLiver transplantCaval resectionPoor qualityMassive hepatomegalyPatient survivalLiving donationPatientsHepatomegalyTransplantationHepatectomyDiseaseIdeal optionLDLTResectionComplicationsTransplantGraft
2005
Immunosuppression in liver transplantation
Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transplantation 2005, 11: 1307-1314. PMID: 16237688, DOI: 10.1002/lt.20614.Peer-Reviewed Original Research
2004
Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation
Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation. Transplantation 2004, 78: 580-583. PMID: 15446318, DOI: 10.1097/01.tp.0000129797.30999.69.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionC virus infectionHepatocellular carcinomaHCV/Liver transplantationVirus infectionChronic hepatitis C virus (HCV) infectionSurvival rateChronic HCV infectionOrthotopic liver transplantationOutcomes of patientsOrgan Sharing dataHCC recurrence rateOverall survival rateLower survival rateHCV groupLT patientsHCV infectionHCC recurrencePatient survivalRecurrence rateUnited NetworkMean agePotential contraindicationsHCC group
1997
Intrathymic spleen cell inoculation and ALS fails to induce tolerance to rat pancreas allografts
Schulak JA, Mulligan DC, Robinson A. Intrathymic spleen cell inoculation and ALS fails to induce tolerance to rat pancreas allografts. Transplantation Proceedings 1997, 29: 1070-1071. PMID: 9123203, DOI: 10.1016/s0041-1345(96)00405-8.Peer-Reviewed Original ResearchAnimalsAntilymphocyte SerumGraft SurvivalHeart TransplantationHistocompatibility Antigens Class IHistocompatibility Antigens Class IIImmunosuppression TherapyLymphocyte TransfusionMajor Histocompatibility ComplexMalePancreas TransplantationRatsRats, Inbred BUFRats, Inbred LewSpleenThymus GlandTime FactorsTransplantation, Homologous